Representing a community of more than 28,000 practitioners and 2,100 programs and practices across the United States, ACCC has the unique ability to promote quality care for the treatment of gastrointestinal cancers. By offering the latest education, resources, and support to our partners, we can work together to improve patient outcomes and address care disparities for those diagnosed with gastrointestinal cancer.
Gastrointestinal cancers can develop anywhere in the digestive tract. The five most common types of gastrointestinal cancer are colorectal, stomach (gastric), liver, esophageal, and pancreatic. Less common are colon, gallbladder, rectal, small intestine, anal, and bile duct cancers. Treatments, which are most effective when cancer is detected early, may include surgery, chemotherapy, radiation therapy, targeted therapy, or immunotherapy.
People who smoke, heavily consume alcohol, or have unhealthy diets are at higher risk for developing gastrointestinal cancers.
St. Elizabeth Cancer Center launched a comprehensive program to perform outreach to patients with outstanding orders for lung, breast, and colon cancer screenings.
ACCC is recognizing National Colorectal Cancer Awareness Month by highlighting the importance of cancer screenings and early detection.
October is liver cancer awareness month, a disease that is the second leading cause of cancer-related deaths globally.
The COVID-19 pandemic had a significant impact on the cancer screening rate. While telemedicine has facilitated care delivery, there is a need for programs aimed at promoting screening. This understanding prompted Mercy Medical Center-Cedar Rapids, Hall-Perrine Cancer Center in Iowa to launch a initiative that has excelled in increasing their colorectal screening rates, and facilitated the provision of high-quality care in the community.
The US has seen a steady decline in the overall incidence of colorectal cancer (CRC) during the past several decades. In 1975, 60 people per 100,000 were diagnosed with colorectal cancer; by 2018, that number had fallen to 34. But overall trends in CRC incidence and outcomes often differ among racial groups and geographic locations. Black Americans are more likely to be diagnosed with CRC than White Americans and more likely to die from it. CRC mortality rates in American Indian and Alaska Native populations have stubbornly stayed put.
To help address the ongoing prevalence of colorectal cancer, ACCC is inviting its members to submit proposals for quality improvement initiatives in treating metastatic forms of this cancer.
Learn how multidisciplinary providers can enhance care for hepatocellular carcinoma patients by improving care capacity and coordination.
The COVID-19 pandemic has had a negative impact in the rate of cancer screening across various states in the United States. Louisiana, Delaware, Kentucky and Northern Michigan serve as vehicles for an analysis of the disparity in cancer screening rates, before and after the pandemic.
An integrated precision tracking program ensures proper follow-up care and surveillance for survivors of colorectal cancer.
ACCC partnered with Pfizer Global Medical Grants to improve biomarker testing practices in metastatic colorectal cancer care, ultimately aiming to provide more personalized and effective care for colorectal cancer patients.
Though the incidence of AIDS-defining cancers has decreased with the use of antiretroviral therapy, numerous studies suggest that non-AIDS-defining cancers (cancers not previously associated with HIV and AIDS) appear to be increasing in incidence.
Presented at 2019 Society of Interventional Radiology Annual Scientific Meeting in Seattle, WA.
Presented at the 2019 ASCO Gastrointestinal Cancers Symposium in San Francisco, CA.